Teva Pharmaceutical Faces FTC Investigation for Patents, Washington Post Says
-- The Federal Trade Commission has opened an investigation into Teva
Pharmaceutical Industries over its patent practices, the Washington Post
reported on Monday.
-- The probe focuses on the Israeli company's refusal to withdraw patents for
asthma inhalers and treatments for chronic obstructive pulmonary
disease from a federal registry called the Orange Book, according to the Post.
-- The FTC claims Teva made small modifications to keep the patents in the registry
and stifle competition, the Post reported.
-- Teva spokesperson Kelley Dougherty told The Wall Street Journal that the
company's patents are properly listed and that Teva "continues to stand
behind the company's intellectual property."
Full article at https://www.washingtonpost.com/health/2024/07/01/teva-patent-pharma-generic-inhaler/
Write to Victor Swezey at victor.swezey@wsj.com
(END) Dow Jones Newswires
July 01, 2024 12:49 ET (16:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks